Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9 by Winther, Stine B et al.
STUDY PROTOCOL Open Access
Randomized study comparing full dose
monotherapy (S-1 followed by irinotecan)
and reduced dose combination therapy
(S-1/oxaliplatin followed by S-1/irinotecan)
as initial therapy for older patients with
metastatic colorectal cancer: NORDIC 9
Stine Braendegaard Winther1*, Pia Österlund2,3, Åke Berglund4, Bengt Glimelius4, Camilla Qvortrup1,
Halfdan Sorbye5, Per Pfeiffer1 - on behalf of the Academy of Geriatric Cancer Research (AgeCare)
Abstract
Background: Metastatic colorectal cancer (mCRC) is a disease of older age, but there is a relative lack of knowledge
about effects of chemotherapy in older patients as they are under-represented in clinical trials. Little data can guide
whether the strategy in older mCRC patients should be a sequential full-dose monotherapy chemotherapy approach
or a dose-reduced combination chemotherapy approach. The oral 5FU prodrug S-1 seems to have less side effects
than capecitabine and should be an optimal drug for older patients, but few data are available. Improved geriatric
assessments are needed to select which older patients should receive therapy.
Methods: The NORDIC 9 trial is a Nordic multicenter randomized phase II study comparing full dose monotherapy
(S-1 30 mg/m2 twice daily days 1–14 every 3 weeks, followed by second line irinotecan 250–350 mg/m2 iv day 1 every
3 weeks or 180–250 mg/m2 iv day 1 every 2 weeks) with reduced dose combination therapy (S-1 20 mg/m2 days
1–14 + oxaliplatin 100 mg/m2 iv day 1 every 3 weeks, followed by second line S-1 20 mg/m2 days 1–14 + irinotecan
180 mg/m2 day 1 every 3 week) for older patients (≥70 years) with mCRC who are not candidates for full-dose
standard combination therapy. Additional bevacizumab (7.5 mg/kg) is optional in first-line. Blood samples and
tumor tissue will be collected to investigate predictive markers. Geriatric screening tools (G-8, VES-13, Timed-Up-
and-Go and Handgrip strength), Charlson Comorbidty Index and quality of life (EORTC QLQ-C30) will be evaluated as
predictors of efficacy and toxicity. The target sample size is 150 patients.
The primary endpoint is progression-free survival and secondary endpoints are time-to-failure of strategy, overall
survival, response rate, toxicity, and correlations between biomarkers, pre-treatment characteristics and geriatric
assessments.
Discussion: The study will add knowledge on how to treat older mCRC patients who are not candidates for standard
combination therapy. Furthermore it may provide understanding of efficacy and tolerability of chemotherapy in older
cancer patients and thus offer a better chance for tailored treatment strategies in these patients.
Trial registration: EU Clinical Trial Register, EudraCT no. 2014–000394-39. Registered 05 May 2014.
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Background
Survival of patients with metastatic colorectal cancer
(mCRC) has increased considerably over the past several
decades. Contributory factors for this improvement are
surgical resection or other ablative techniques for meta-
static disease, a more strategic approach to the delivery
of systemic therapy with a continuum of care, better
selection of patients to different treatments and more
lines of effective anticancer drugs [1].
The backbone of medical treatment of mCRC is
5-fluorouracil (5-FU). Since about two decades, it is
seldom given alone but biochemically modulated with
calcium folinate due to higher response rates and likely
improved survival [2]. The oral prodrugs of 5-FU (cape-
citabine, UFToral and S-1) are as efficient as modulated
5-FU and efficacy is further increased when 5-FU is
combined with irinotecan or oxaliplatin [1, 3]. Combin-
ation regimens are often the best first-line choice, but
monotherapy is an alternative in some clinical situations
based upon the results of several trials. In both the
CAIRO [4], FOCUS1 [5] and FFCD 2000–05 trials [6]
unselected patients with previously untreated mCRC
were randomized between a sequential strategy and com-
bination therapy. In the FOCUS2 [7] and FFCD 2001–02
[8] trials, the doublet strategy in older patients with
mCRC was explored, in FOCUS2 with a population of
patients who were not candidates for full-dose chemother-
apy. All studies showed that it is safe to start monotherapy
if followed by new therapy upon progression.
Median overall survival (OS) often exceeds 24 months
for mCRC patients included in clinical trials. In unse-
lected populations of mCRC patients, however, median
OS is only around 12 months [9–11] although, in one of
the population-based studies [12], median OS was
21.3 months in the subgroup of patients (36%) treated
with combination chemotherapy as in a clinical trial. The
short OS in general populations of mCRC patients is
mainly for a short survival in patients above 70–75 years
of age and in patients not receiving any chemotherapy due
to a variety of reasons [12, 13]. The reported OS improve-
ment over time in mCRC patients is mainly seen in youn-
ger patients and only minor improvements are found in
older patients [14]. In a large community-based study,
older patients (65+ years) were less likely to receive first-
line doublet chemotherapy and also less likely to receive
irinotecan, oxaliplatin, and bevacizumab during the entire
course of the disease [15].
In a combined analysis of more than 2500 patients
treated with different irinotecan/5-FU schedules in four
first-line phase III trials, the authors concluded that
older patients (70+ years) who fulfilled the inclusion
criteria of the trials had similar benefits of treatment and
similar risk of toxicity as younger patients, and these
results have been confirmed in other studies including
systematic reviews [16–19]. A comparable outcome in
patients below or above 70 years included in randomized
trials is reasonably explained by inclusion of only the
very fittest older patients, based on strict inclusion cri-
teria, e.g. appropriate performance status and sufficient
organ functions, but these patients are not representative
of the majority of older patients cared for in the onco-
logical clinics [20]. This has an impact on our perception
of standard therapy, as colorectal cancer (CRC) is a
disease of older age with approximately 50% of the
patients being 70 years or older [9, 21]. From 2001 to
2005 the median age of patients with mCRC included in
clinical trials was only 62 years [22], while the median
age at mCRC diagnosis is 71–74 years according to
cancer registries [14].
In clinical practice many oncologists recommend full-
dose monotherapy or reduced dose combination therapy
(without much evidence) in older and/or frail patients.
In the FOCUS1 trial [5], where single agent therapy
versus combination chemotherapy was explored, the
median age was only 64 years, despite permissive entry
criteria and no upper age limit, and a retrospective sur-
vey showed that almost twice as many patients had been
treated off-trial during the same period, frequently using
reduced-dose or single-agent schedules. The most
frequent reasons for non-inclusion were physicians’
concerns about the adverse effects of standard-dose
treatments and patients’ wishes to avoid toxic effects.
The authors therefore designed FOCUS2 [7] for patients
where the treating oncologist considered standard full-
dose regimens to be unsuitable. A total of 459 patients
(median age 74 years) were randomized to reduced dose
monotherapy or reduced dose oxaliplatin combination
therapy, with a planned dose escalation in patients with
no or few side effects. However, dose escalation was only
effectuated in one third of the patients. Combination
therapy more than doubled response rate (from 13% to
35%) and marginally prolonged progression-free survival
(PFS) (HR 0.84 (0.69–1.01), p = 0.07), but OS was not
improved (HR 0.99 (0.81–1.18)).
In a recent French phase III trial (FFCD-2001-02),
where 282 mCRC patients aged ≥75 years received
either first-line monotherapy with 5-FU or FOLFIRI, no
significant differences in PFS (5.2 months vs. FOLFIRI
7.3 months, HR 0.84 (0.66–1.07), p = 0.15) or OS
(14.2 months vs. 13.3 months, HR 0.96 (0.75–1.24))
were found [8]. In line with these data, a recent meta-
analysis showed that combination chemotherapy pro-
longed PFS but not OS with an increased risk of toxicity in
older patients [23].
Further development of antineoplastic drugs may lead
to agents with a potentially more favorable toxicity pro-
file which may be of benefit especially for older cancer
patients. S-1 (Teysuno®) is a third generation oral
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fluoropyrimidine comprised of tegafur, a pro-drug of
5-FU, and two modulators of 5-FU metabolism; gimeracil
and oteracil [24]. S-1 provides sustained 5-FU plasma
concentrations with reduced toxicities like hand-foot-
syndrome (HFS) and probably cardiotoxicity and diar-
rhoea, due to the addition of the modulators [25–27].
Randomized Asian studies in mCRC patients have shown
that S-1 is as effective as 5-FU or capecitabine as mono-
therapy, and in combination with oxaliplatin [28, 29] or
irinotecan [30]. In Japan S-1 is approved for the treatment
of several cancers including gastric, colorectal and pancre-
atic cancers, but in the European Union presently only for
gastric cancer [24].
Because of higher activity of CYP2A6 and thereby
more effective conversion of S-1 to 5-FU in Caucasians,
the optimal dose is lowered in Caucasians compared to
Asians [24, 26]. In an observational chart review the use
of S-1 as monotherapy (30 mg/m2 twice daily on days
1–14 every 3 weeks) and in combination (25 mg/m2
twice daily on days 1–14 every 3 weeks) with oxaliplatin
or irinotecan, respectively, in 71 older mCRC patients
was evaluated [26]. In all three settings S-1 was well-
tolerated with a low rate of clinical and haematological
adverse events, and especially a very low incidence of
HFS was found. Furthermore the treatment indicated
comparable efficacy to standard regimens in mCRC.
However further prospective Western studies are needed
to confirm efficacy and safety of S-1 in young and older
populations.
Bevacizumab has in randomized studies, as a part of
combination therapy improved efficacy in mCRC
patients [31–34]. Retrospective cohort studies indicate a
similar benefit on a population level [35, 36]. In a recent
study, S-1 plus bevacizumab therapy was effective and
safe for older (median age 75 years) mCRC patients [37].
In the SALTO trial, S1 plus bevacizumab was as effective
as capecitabine plus bevacizumab with a significantly
lower incidence of HFS [38].
Based on these facts, the ongoing NORDIC 9 trial was
initiated to compare full dose single agent S-1 therapy and
dose-reduced combination therapy in older patients not
considered candidates for standard combination therapy,
hypothesizing that reduced combination therapy improves
efficacy compared to fulldose monotherapy.
Geriatric assessments
A major challenge in the treatment of older cancer
patients today is to select the patients who can tolerate
and benefit from treatment. Comorbidity, polypharmacy,
different state of nutrition, functional and psychosocial
capabilities including cognition are all elements of
pivotal character when an overall assessment of the older
patient is made [39]. Several attempts to develop tools for
this evaluation have been made. The Comprehensive
Geriatric Assessments (CGA) is recommended by the
International Society of Geriatric Oncology (SIOG)
[40, 41], but CGA is too time-consuming to be performed
in a routine oncological clinical setting. Therefore several
screening tools to identify the patients, who would benefit
from a CGA and potential treatment, have been tested. In
the NORDIC 9 trial, we have chosen some of the most
promising and least time-consuming tests (G-8, VES-13,
Timed-Up-and-Go and Handgrip strength) to evaluate
their predictive and prognostic value.
 The G-8 is an 8-item screening tool including
nutrition, mobility, neuropsychological problems,
number of medications, self-perception of health
and age [42]. The G-8 is scored by a nurse and takes
approximately 5 min.
 The Vulnerable Elders Survey (VES-13) is a 13-item
self-administered instrument based upon age, self-
rated health and the ability to perform physical and
functional activities. It predicts functional decline
and mortality [43, 44] and takes approximately
5 min to fill out.
 Timed-up-and-go-test (TUG) assesses the physical
status of the older patient. The patient is
observed and timed while he/she rises from an
armchair, walks 3 metres, turns, walks back, and
sits down again [45].
 Handgrip strength (GS) is measured with a hand
dynamometer and reflects the upper extremity
strength. It correlates to patients’ overall muscle
strength, bone density, nutrition status and frailty [46].
Furthermore
 Charlson Comorbidity Index is scored by a
physician and takes approximately 5 min.
 Quality of Life (QoL) by EORTC-QLQ-C30 is
completed at baseline and after 3rd and 6th course
of treatment, to supplement the overall assessment.
Methods/design
Design
NORDIC 9 is an open multicenter randomized phase II
trial aiming at investigating the efficacy of full dose
monotherapy (S-1 followed by second line irinotecan
upon progression) and a reduced dose combination
therapy (S-1/oxaliplatin followed by second line S-1/
irinotecan) as initial therapy for older (≥70 years)
mCRC patients who are not candidates for full dose
standard combination chemotherapy as evaluated by
the treating physician (Fig. 1). Additional therapy with
bevacizumab in first-line setting is optional, but that
decision should be made before randomization.
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Participants
One hundred and fifty patients will be enrolled at 20 on-
cologic departments in Finland, Norway, Sweden and
Denmark. All patients must be 70 years or older, have
histologically verified colorectal adenocarcinoma, non-
resectable mCRC and not be candidate for standard full-
dose combination chemotherapy as evaluated by the
treating physician. Other inclusion criteria are WHO
performance status 0–2, life expectancy of at least
3 months, no prior chemotherapy except adjuvant fluor-
opyrimidine therapy completed more than 180 days be-
fore randomization, no evidence of CNS metastasis, and
adequate hematological, kidney (GFR > 30 ml/min, but
if calculated GFR is ≤70 ml/min, GFR must be mea-
sured) and liver function.
The enrollment started in March 2015 and target re-
cruitment period is estimated to be 24 months and
follow-up period/end date is estimated to be 6 months
after inclusion of the last patient. Randomization will be
conducted as a block randomization stratified according
to institution and planned therapy with bevacizumab.
All patients must provide written informed consent.
Treatment
Patients will be randomized to receive:
Arm A: Full dose single agent strategy
First-line: S-1 30 mg/m2 twice daily days 1–14 every
3 weeks followed upon progressive disease (PD) by
Second line: Irinotecan 250 mg/m2 iv day 1 every
3 weeks or irinotecan 180 mg/m2 iv day 1 every
2 weeks (optional). In the absence of toxicity (except
alopecia) above grade 1, it is recommended to
increase the irinotecan dose in steps to 350 mg/m2 iv
day 1 every third week or irinotecan 250 mg/m2 iv
day 1 every second week.
or
Arm B: Reduced dose (80%) combination-therapy
strategy
First-line: S-1 20 mg/m2 twice daily days 1–14 and
oxaliplatin 100 mg/m2 iv day 1 every 3 weeks
followed upon PD by
Second line: S-1 20 mg/m2 twice daily days 1–14 and
irinotecan 180 mg/m2 iv day 1 every 3 weeks
Bevacizumab (7.5 mg/kg iv day 1) may be added to
first-line chemotherapy (monotherapy or combination)
at the discretion of the treating physician.
Blood samples (serum and EDTA plasma) and tumor tis-
sue will be collected for future investigations of
biomarkers.
The Geriatric screening tools (GST) (G-8, VES-13,
Timed-Up-and-Go, Handgrip strength), Charlson Co-
morbidity Index and QoL will be completed before
randomization.
Dose modifications
In patients with GFR 30–49 ml/min, the dose of S-1
must be reduced with 5 mg/m2 (from 30 mg/m2 to
25 mg/m2 or from 20 mg/m2 to 15 mg/m2).
When dose reduction is needed during therapy because
of toxicity, the dose of S-1 will be reduced with 5 mg/m2
(from 30 mg/m2 to 25 mg/m2 or from 20 mg/m2 to
15 mg/m2) and the dose of oxaliplatin or irinotecan will
be reduced with 25%.
Duration of therapy
Treatment is recommended until progression, unaccept-
able side-effects, patients’ wish of ending treatment or
patients’ wish for chemo-holiday. After disease progres-
sion, the patients will be offered second-line therapy,
which will continue until new progression.
Evaluation of treatment delivery
After every 9 weeks a CT-scan will be performed to
evaluate time of progression in all patients and radio-
logical response in patients with measurable disease
(according to RESIST criteria 1.1).
Post treatment evaluation will be assessed by clinical
and radiological tumor evaluation every 2 months until
second progression is diagnosed.
Safety
Adverse events will be evaluated according to NCI-CTC
version 4.0 for all patients for 28 days following the last
dose of study drug.
When 50 patients are included, a safety analysis
(toxicity and dose-intensity) after the three first cycles of
therapy will be conducted and evaluated by the protocol
Fig.1 Study design of the NORDIC 9 trial
Winther et al. BMC Cancer  (2017) 17:548 Page 4 of 7
committee to ensure tolerability. Inclusion of patients
may continue during safety analysis.
Study objectives
The primary endpoint is PFS. Secondary objectives are
Time-To-Failure-of-Strategy (TTFS) as defined by Allegra
et al. [47], OS as deaths of all causes, response rate (RR)
(investigator evaluated) according to RECIST criteria 1.1
in patients with measurable disease, toxicity, QoL as
described by EORTC QLQ-C30, correlation between
biomarkers and outcome as well as evaluation of pre-
treatment characteristics and geriatric screening tools as
predictive markers for efficacy and toxicity.
PFS, TTFS, and OS will be calculated from the date of
randomization to the first date of radiological or clinic-
ally documented progression to first-line therapy (PD1),
first date of documented progression to second line ther-
apy (PD2), or death.
Statistics
The definition of the target sample size is made based
on prior data indicating that median PFS on single agent
is 4 months in this patient group, but may be as long as
8 months in patients receiving single agent with bevaci-
zumab [7, 32]. Half of the patients may be candidates for
additional bevacizumab, and thus, median PFS for the
group of patients receiving single agent therapy may be
6 months. If median PFS for the experimental group
(combination therapy, arm B) is 9 months, we need to
study 71 experimental patients and 71 control patients
to be able to reject the null hypothesis that the experi-
mental and control survival curves are equal with prob-
ability (power) 0.8 and a type I error probability of 0.2.
To ensure 142 evaluable patients we will include 75
patients in each arm, a total of 150 patients.
PFS and OS data will be estimated by Kaplan-Meier
methods and compared with log-rank test. Adverse
events will be evaluated in an intention-to-treat-popula-
tion (all patients who have received at least one course
of chemotherapy). The calculations described above are
based on the primary end-point. Calculations on the
secondary end-points are only hypothesis generating and
thus explorative. Our study includes several lines of
therapy, which will impair the possibility of finding a
significant difference in OS.
Discussion
This study is conducted to evaluate two treatment strat-
egies in older mCRC patients - full-dose single agent
therapy or dose-reduced combination therapy. Patients
are not candidates for full dose double or triple com-
bination therapy either because of frailty, very old age,
patient preference or because the treating physician
recommends less intensive therapy [1], and thus
constitute a heterogeneous group. With this study
population we have tried to imitate the older popula-
tion who often challenges physicians in clinical every-
day life and where the decision on which treatment
regimen to choose is not clear-cut.
As S-1 seems to have a better toxicity profile com-
pared to capecitabine, especially because of a lower inci-
dence of HFS [26], it may be a suitable drug for the
study population.
A randomized phase II study, AVEX [32], showed that
bevacizumab improved efficacy (RR and PFS) of single
agent capecitabine in fit older patients. Therefore it is
optional to add bevacizumab to chemotherapy at the
discretion of the treating physician in the trial.
Standard treatment in patients with mCRC includes
chemotherapy in several lines with an expanding range
of treatment options [1]. Therefore we have planned a
continuum of care/strategy for patients including both
first and second line therapy as part of the trial.
If the study reaches the desired end-point for efficacy,
it suggests that reduced combination therapy becomes
the standard treatment for patients with mCRC who are
not candidates for standard full-dose combination ther-
apy. Future studies will be needed to confirm this and
perhaps evaluate the potential benefit of adding bevaci-
zumab to all patients in this particular study population.
SIOG recommends that future research focuses on the
ability of screening tools to build clinical pathways and
to predict different outcome parameters [48]. We have
in the trial chosen to include several geriatric screening
tools, which have sensitivity and specificity comparable
to a full CGA, but are less time-consuming [48, 49].
Most of the studies performed on geriatric screening
tools have been retrospective and performed in patient
populations with heterogeneous cancers [39]. We will
evaluate the chosen geriatric screening tools in a pro-
spective study design in a population of older mCRC
patients in order to predict efficacy and toxicity of the
oncological treatment and search for at-risk individuals.
If shown to be valid and relevant, the screening tools
may in the future be part of routine screening in the
treatment decision of geriatric patients [39].
Trial Status
A total of 120 patients have been enrolled by the 1st of
January 2017.
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